The DIDO1 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited population of human hepatocellular carcinoma cells engineered to disrupt the DIDO1 gene. This polyclonal knockout model provides a robust loss-of-function system for investigating the tumor-suppressive roles of DIDO1 in a hepatic epithelial context. The polyclonal format offers a representative pool of edited genotypes, minimizing clonal selection biases and supporting studies that benefit from mixed allelic disruption. The product is an essential tool for examining TGF-beta-induced apoptosis and its dysregulation in liver cancer.
Huh-7 is a well-established cell line derived from the liver tumor of a male patient with hepatocellular carcinoma. These adherent epithelial cells carry a homozygous mutant p53 (Y220C), which inactivates the canonical p53-mediated apoptotic pathway. Consequently, Huh-7 cells depend on p53-independent mechanisms for programmed cell death, making them a sensitive host for studying alternative apoptotic regulators. The line is extensively characterized and widely used in research on liver cancer biology, drug metabolism, and TGF-beta signal transduction, providing a disease-relevant platform for knockout studies.
DIDO1 (Death-Inducer Obliterator 1) encodes a nuclear protein that functions as a pro-apoptotic effector downstream of the TGF-beta receptor cascade. Upon TGFB1 ligand binding, TGFBR1 and TGFBR2 activate SMAD2 and SMAD3 through phosphorylation, leading to complex formation with SMAD4 and nuclear translocation. Within the nucleus, the SMAD complex interacts with DIDO1 to drive transcriptional programs that culminate in caspase activation. Key downstream mediators include CASP3, CASP9, and BAX, which promote mitochondrial outer membrane permeabilization and apoptotic execution. DIDO1 thus mediates a critical link between TGF-beta signaling and the intrinsic apoptosis pathway, operating independently of p53.
In hepatocellular carcinoma, loss of DIDO1 function disrupts the tumor-suppressive arm of TGF-beta signaling, which normally counteracts hepatocarcinogenesis in early stages. The DIDO1 knockout in Huh-7 cells models this impairment, rendering cells resistant to TGF-beta-induced apoptosis despite the presence of mutant p53. This recapitulates a key feature of aggressive liver cancers, where evasion of cell death mechanisms contributes to tumor progression and therapy resistance. The model enables dissection of the molecular interplay between TGF-beta and p53-independent apoptotic pathways, offering insights into tumor biology and potential therapeutic targets.
These polyclonal knockout cells are suited for a range of functional assays central to TGF-beta and apoptosis research. Typical applications include western blotting for cleaved caspase-3 and PARP to confirm apoptotic inhibition, RT-qPCR for DIDO1 and TGF-beta-responsive genes, and flow cytometry with Annexin V and propidium iodide for quantitative apoptosis detection. Co-immunoprecipitation can validate SMAD2/3/4 interactions with DIDO1, while luciferase reporters measure TGF-beta pathway transcriptional activity. The model is also valuable for drug sensitivity screens to identify compounds that restore apoptosis in TGF-beta-resistant tumors. For additional technical details and support, researchers are invited to contact Ascent Research.
